XBiotech (XBIT)
Develops human-derived monoclonal antibodies through integrated Austin research, clinical development and manufacturing.
Something off on this page? Send us feedback.
Develops True Human antibody candidates from human blood samples and sold bermekimab to Janssen. Its integrated Austin operation connects discovery, clinical development and manufacturing.
Discovers and develops True Human monoclonal antibodies, cloned from individual donors with natural immunity to disease. Its work spans discovery, manufacturing, formulation, preclinical development, regulatory submissions and human clinical trials.
Operations center on an Austin campus that combines research, development and manufacturing infrastructure. The company sold the bermekimab antibody to Janssen, while retaining rights to develop comparable True Human antibodies for non-dermatological indications.
Clinical and regulatory progress shape the pipeline. The planned Hutrukin stroke study is on hold pending clarity on cancer and arthritis regulatory paths, and the rheumatology program was paused after a rheumatoid-arthritis Phase II study missed its primary endpoint.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $109.5M · Total debt $0 · Total assets $133.7M · Shareholders' equity $128.5M
- Revenue
- $0
- Operating income
- −$6.1M
- Net income
- −$6.7M
No dividends on record.
| Institutions38 holders · as of Mar 31, 2026 | 6.54% | 1.99M shares | |
| Insiders6 holders · as of Jan 23, 2026 | 46.28% | 14.11M shares | |
| Otherremainder | 47.18% | 14.39M shares |
30.49M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
John Simard1Insiderdirector, 10 percent owner, officer: Chief Executive Officer | 18.76% | 5.72M | 13Gfiled Jan 23, 2026 ↗ |
Thomas GutInsider10 percent owner | 12.84% | 3.91M | 13Gfiled Feb 10, 2023 ↗ |
W. Thorpe MckenzieInsiderdirector, 10 percent owner | 9.86% | 3.01M | 13Gfiled Jan 23, 2026 ↗ |
Lombard International Assurance S.A.Insider | 3.65% | 1.11M | 13Gfiled Jan 12, 2023 ↗ |
BlackRock, Inc.Institution | 0.96% | 293,104 | 13Fas of Mar 31, 2026 |
| See all 25 → | |||
- John Simard's transaction reports restate only vehicles that traded; the 2026 ownership statement (5.72M) is used instead.
13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more
Insider tradesForm 4
No open-market trades in the last 12 months.
- Novartis (ADR)
Cosentyx spans active AS and nr-axSpA in the United States
- AbbVie
RINVOQ is approved for active AS and nr-axSpA
- Eli Lilly
Taltz is approved for active AS and nr-axSpA
- Amgen
ENBREL is an established biologic for active AS
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| XBiotech | $2.20 | −0.90% | $66.8M | — | 18.3 | — | — |
| Novartis (ADR) | $162.45 | +0.01% | $308.79B | 24.5 | 17.3 | 5.6 | +0.9% |
| AbbVie | $264.00 | +0.88% | $462.37B | 73.7 | 17.2 | 7.2 | +10.2% |
| Eli Lilly | $1,167.77 | +0.72% | $1.09T | 38.9 | 28.4 | 13.7 | +47.7% |
| Amgen | $443.00 | +0.04% | $239.00B | 27.5 | 18.9 | 6.3 | +9.7% |
| Median | 33.2 | 18.1 | 6.7 | +9.9% |